Impetis Biosciences, a Tata group subsidiary, has partnered with US based Vyome Holdings to license two experimental selective JAK inhibitors. The therapies target rheumatoid arthritis and hair thinning while being designed to lower safety risks seen with earlier JAK treatments, marking a notable push toward refined, risk aware drug development.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
